Introduction: Pseudomonas aeruginosa is a biofilm forming pathogen that challenges clinical and industrial settings. Many natural products and surfactants have been screened and valued for their ...anti-biofilm capacity. In this study we assessed the inhibitory effect and molecular mechanism of action of ginger extract (Zingiber officinale Rosc.), wild blueberry extract (Vaccinium angustifolium), and polysorbates (PS20/PS80) on biofilm formation.
Methodology: Ginger and wild blueberry extractions were done using ethanol and distilled water, respectively. Hexane and methanol were used for extracts’ liquid-liquid portioning. LC-HRMS was performed to obtain extract fractions. Efficacy of the crude extracts, fractions, and polysorbates was assessed on P. aeruginosa PAN14 growth and biofilm. Transcription levels of biofilm encoding genes ndvB, pelC, algC and quorum sensing genes lasI, lasR, rhlI, rhlR were evaluated by RT-qPCR.
Results: Extracts and polysorbates concentrations did not affect P. aeruginosa growth. Biofilm assay showed a reduction in biofilm when 5% ginger, 25% wild blueberry extracts, 0.2% PS20, and 0.25% PS80 were added. LC-HRMS analysis of ginger extract showed abundant gingerol in the hexane layer. Wild blueberry chromatograms showed various constituents differing between their peel and pulp, and pulp extracts. RT-qPCR showed decreased transcription levels of exopolysaccharide and quorum sensing genes with a 363.6 folds reduction in ndvB upon treatment with 25% wild blueberry peel and pulp extract.
Conclusion: These results shed light on the mechanism of action of ginger and wild blueberry constituents as well as PS20/80 on P. aeruginosa biofilm formation. Future mouse model experiments are useful to test biofilm inhibition in-vivo.
•The surface-associated multicellular biofilm growth state protects cells from harsh environmental conditions including physical and chemical stresses.•Bacterial biofilms are adaptively resistant to ...antibiotics and immune clearance.•Biofilms are associated with two third of all infections especially chronic and device-related infections.•Generally speaking antibiotics were developed for free swimming bacteria; thus, biofilm-specific therapies are required.•Certain features of biofilm development, such as surface adherence, extracellular matrix formation, quorum sensing, and highly regulated biofilm maturation and dispersal are being investigated as targets for biofilm-specific treatments.
The growth of bacteria as structured aggregates termed biofilms leads to their protection from harsh environmental conditions such as physical and chemical stresses, shearing forces, and limited nutrient availability. Because of this highly adapted ability to survive adverse environmental conditions, bacterial biofilms are recalcitrant to antibiotic therapies and immune clearance. This is particularly problematic in hospital settings where biofilms are a frequent cause of chronic and device-related infections and constitute a significant burden on the health-care system. The major therapeutic strategy against infections is the use of antibiotics, which, due to adaptive resistance, are often insufficient to clear biofilm infections. Thus, novel biofilm-specific therapies are required. Specific features of biofilm development, such as surface adherence, extracellular matrix formation, quorum sensing, and highly regulated biofilm maturation and dispersal are currently being studied as targets to be exploited in the development of novel biofilm-specific treatments. Using Pseudomonas aeruginosa for illustrative purposes, this review highlights the antibiotic resistance mechanisms of biofilms, and discusses current research into novel biofilm-specific therapies.
Biofilm-associated infections represent one of the major threats of modern medicine. Biofilm-forming bacteria are encased in a complex mixture of extracellular polymeric substances (EPS) and acquire ...properties that render them highly tolerant to conventional antibiotics and host immune response. Therefore, there is a pressing demand of new drugs active against microbial biofilms. In this regard, antimicrobial peptides (AMPs) represent an option taken increasingly in consideration. After dissecting the peculiar biofilm features that may greatly affect the development of new antibiofilm drugs, the present article provides a general overview of the rationale behind the use of AMPs against biofilms of medically relevant bacteria and on the possible mechanisms of AMP-antibiofilm activity. An analysis of the interactions of AMPs with biofilm components, especially those constituting the EPS, and the obstacles and/or opportunities that may arise from such interactions in the development of new AMP-based antibiofilm strategies is also presented and discussed. This article is part of a Special Issue entitled: Antimicrobial Peptides edited by Karl Lohner and Kai Hilpert.
Display omitted
•Biofilm-associated infections are one of the major threats of modern medicine.•AMPs may represent a promising therapeutic approach for biofilm-associated infections.•AMP-activity may rely on bactericidal effect or interference with biofilm lifestyle.•Interaction with polymers of biofilm matrix may hamper AMPs' antibiofilm activity.
El envejecimiento progresivo de la población y el aumento de las afecciones articulares degenerativas generan un incremento en las patologías óseas, comprometiendo al aparato locomotor. Esto da lugar ...a un aumento de fracturas y defectos óseos, difíciles de tratar en algunos casos.Los avances en la ciencia de materiales y la biomedicina son determinantes en este ámbito, ya que buscan diseñar nuevos biomateriales para posteriormente implantarlos con el fin de reemplazar, reparar y regenerar el tejido óseo dañado. Sin embargo, en algunas ocasiones, su aplicación clínica puede presentar varios problemas. Uno de estos problemas es la posible infección bacteriana tras la intervención quirúrgica, que generaría la formación de un biofilm. Esto puede inhibir el efecto de antibióticos en esa zona, requiriendo una segunda intervención quirúrgica. La plata es un agente citotóxico que podría utilizarse como medida preventiva para evitar la formación de un biofilm bacteriano en implantes, mediante su incorporación al propio biomaterial.El propósito de este trabajo es documentar el uso de las nanopartículas de plata metálica como agente antibacteriano. Se indicará su mecanismo de acción frente a las bacterias y su posible toxicidad en el organismo humano.
Dabei gelte es insbesondere dem Exsudatmanagement Rechnung zu tragen, um Wundrand und -umgebung zu schÜtzten, die mikrobielle Last der Wunde zu reduzieren und zu hÄufige Verbandswechsel oder ...Manipulation an der Wunde zu vermeiden.
PDF
